FDA Approves Zolbetuximab-clzb with Chemotherapy for Gastric or Gastro-Oesophageal Junction Adenocarcinoma By Ogkologos - November 13, 2024 367 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved the VENTANA CLDN18 (43-14A) RxDx Assay as a companion diagnostic device Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Inavolisib Plus Palbociclib–Fulvestrant Prolongs PFS in Patients with PIK3CA-mutated, HR-positive, HER2-negative... November 28, 2024 Sentinel Lymph Node Biopsy Navigated Neck Dissection Is Not Inferior to... April 22, 2021 Quitting Smoking Improves Survival in People with Lung Cancer September 14, 2021 Why I Work to Bridge the Gap Between People With Cancer... May 27, 2021 Load more HOT NEWS FDA Approves Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma Study Offers Insights on Health Problems among AYA Cancer Survivors Holiday Lights Are My Favorite Thing Glioblastoma Study Highlights Sex Differences in Brain Cancer
